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CONTINUING EDUCATION
Drug-induced Cardiotoxicity of Oncological Agents: Monitoring 
Parameters, Prevention, and Future Chemotherapy
By Sarah Nguyen, Pharm.D. Candidate 2015; Mary Nguyen, PharmD Candidate 2015; Laura Tsu, Pharm.D., BCPS; 
Midwestern University College of Pharmacy - Glendale
Goal:
The goal of this article is to educate pharmacists of the impact 
of cardiotoxicity on chemotherapy regimens including key 
cancer agents, monitoring parameters, prevention, and the 
future of chemotherapy..
Objectives for Pharmacists:
At the conclusion of this lesson, successful participants should 
be able to:
1. Determine the clinical significance of cardiotoxicity in can-
cer therapy.
2. Describe the mechanism of action and cardiotoxic effects of 
anthracyclines, mitoxantrone, trastuzumab, 5-fluorouracil, and 
bortezomib.
3. Compare the cardiotoxicity safety profiles of the different 
HER2 inhibitors and their roles in HER2 positive breast cancer
4. Evaluate the treatment options, monitoring parameters, 
and prevention of anti-cancer drug-induced cardiotoxicity. 
Objectives for Technicians: 
#1-3 above (same as pharmacists) 
4. Describe the treatment options, monitoring parameters, 
and prevention of anti-cancer drug-induced cardiotoxicity. 
Introduction
        Cancer is the second leading cause of death in the United 
States, with a 5 year survival rate of 68%. This accounts for 1 in 
4 deaths in the US. In 2013, 1.6 million Americans were diag-
nosed with cancer, and approximately 585,720 Americans are 
expected to die in 2014 from cancer.1 Due to developments in 
early diagnosis and therapies, cancer survival rates have 
greatly improved. Emerging anti-cancer drugs have been 
increasingly valuable in treatments of many cancers and have 
made significant advances in the field of oncology. However, 
a caveat of many of the widely used, highly effective agents is 
that they are associated with cardiotoxic effects; this increases 
cardiovascular morbidity in patients on these regimens. 
Anti-cancer drugs target cell signaling pathways, which 
inadvertently affect myocardial cells. Because of this, there 
has been a development of cardio-oncology, which is aimed 
at cardiovascular care for oncology patients. This new focus is 
highly relevant in the treatment of cancers as the cardiotox-
ic effects have led to the discontinuation of many regimens, 
which have been shown clinically to slow tumor growth and 
lead to remission otherwise. Drugs which are highly associated 
with cardiotoxic side effects include anthracyclines, mitoxan-
trone, trastuzumab, and 5-fluorouracil. The cardiotoxic effects 
of these agents differ based on their target and mechanism 
of action. Hence, pharmacists must be aware of these 
myocardial toxic effects to effectively monitor cardiac 
function of oncology patients under their care. As the 
incidence of myocardial side effects increases and are 
taken into account in the treatment of many cancers, 
promising developments of newer anti-cancer agents 
have arisen for the discipline of cardio-toxicity includ-
ing: lapatinib, pertuzumab, and trastuzumab emtan-
sine. 
Anthracyclines
        Anthracyclines are a class of cytotoxic antibiotic 
commonly used to treat cancer. The class includes the 
drugs: daunorubicin (DaunoXome, Cerubidine), doxo-
rubicin (Doxil, Adriamycin, Lipodox), epirubicin (El-
lence), idarubicin (Idamycin), and valrubicin (Valstar).  
They work by inhibiting DNA and RNA synthesis 
through direct binding to DNA in addition to inhibiting 
DNA repair.2 Consequently, the lack of functional DNA 
and RNA deprives malignant cells of basic resources 
for survival, a useful property of an anti-cancer agent. 
Liposomal formulations of anthracyclines, such as 
Doxil and Lipodox, are generally the preferred ana-
logue due to its accumulation and releasing proper-
ties. Their advantages stem from their properties of 
preferential accumulation and prolonged release with-
in the tumor environment; thus, lowering accumula-
tion in healthy tissue and adverse effects.3 Although 
anthracyclines are beneficial in cancer treatment, it 
also has concerning adverse effects such as cardiotox-
icity, cardiomyopathy, declined left ventricular ejection 
fraction (LVEF), and congestive heart failure (CHF).4 An 
alarming factor is that anthracycline-induced cardio-
toxicity is dose-related and tends to be progressive 
and irreversible, which can add undesirable complica-
tions to vulnerable cancer patients.5 Therefore, car-
diotoxicity is a major limitation in the usage of anth-
racycline in the treatment of cancer, requiring critical 
monitoring and evaluation within an interdisciplinary 
setting of pharmacists and oncologists.
        Anthracycline-induced cardiotoxicity can be 
categorized into three types. The first type is the 
acute or sub-acute injury that may occur immediately 
after treatment. This type is more rare and includes 
conditions such as transient arrhythmia, pericardi-
tis-myocarditis syndrome, or acute failure of the left 
ventricle.6 The second type is chronic cardiotoxicity, 
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the more common and clinically important form of damage, 
which includes cardiomyopathy.6 The third type of cardio-
toxicity manifests years after treatment, leading to late-on-
set arrhythmia and ventricular dysfunction.6 The exact cause 
of anthracycline-induced cardiotoxicity is uncertain but 
the proposed mechanisms include reactive oxygen species 
(ROS) leading to membrane damage, lipid peroxidation, car-
diomyocyte apoptosis or necrosis, disruption of sarcomere 
structure, or altered ability of cardiac myocyte contraction.5
       When the anti-cancer benefits of anthracycline out-
weigh the risks of cardiotoxicity, the common methods to 
monitor patient’s conditions throughout treatment include 
an echocardiography (ECHO) and multiple gated acquisition 
(MUGA) scan. ECHO measures LVEF and indicates cases 
of left ventricle dysfunction (LVD) that denotes anthracy-
cline-induced cardiotoxicity. However, ECHO may be re-
garded as insensitive in detecting cardiotoxicity at an early 
stage due to the fact that significant changes in LVEF usually 
presents upon substantial myocardial damage. On the other 
hand, a normal LVEF does not exclude the possibility of car-
diotoxicity in the future. Usually, an LVEF less than 50% or a 
LVEF decrease of 10% or greater from baseline constitutes 
for discontinuation of the anthracycline. On the other hand, 
the MUGA scan measures cardiac function but it has the 
disadvantage of radioactivity exposure and limited informa-
tion on cardiac structure and diastolic function.7
       There are many risk factors for anthracycline-induced 
cardiotoxicity that pharmacists and oncologists should 
be aware of. The biggest risk factor is exceeding the rec-
ommended maximum cumulative lifetime dose of anth-
racyclines. Others include prior anthracycline treatment, 
concurrent use of other cardiotoxic agents, history of 
cardiovascular disorders, older and younger age, and female 
gender.5 As anthracycline cardiotoxicity is progressive and 
irreversible, it is critical to know the maximum cumulative 
dose of the specific anthracycline utilized. The recommend-
ed lifetime cumulative doses according to the package 
inserts are 550 mg/m2 for doxorubicin8, 400 mg/m2 for 
daunorubicin9, and 900 mg/m2 for epirubicin in adults.10 
However, pediatrics is a special vulnerable population that 
even the smallest dose of anthracycline may induce cardiac 
complications.11 In addition, cardiotoxicity of anthracyclines 
is peak-related. Therefore, utilizing continuous infusions 
(24-48 hours) as opposed to bolus administration (5-15 
minutes) will lower peak serum concentration and decrease 
the risk of acute cardiotoxicity.11 
       Once anthracycline-induced cardiotoxicity is present 
in a patient, preventative care should be implemented to 
prevent the condition from worsening and recurring. A 
common secondary prevention measure is a cardioprotec-
tive intravenous agent, dexrazoxane (Totect, Zinecard).  The 
proposed mechanism of dexrazoxane is the metal chelation 
that reduces anthracycline-induced free radical damage. 
Two meta-analyses have shown that dexrazoxane sig-
nificantly decreases the risk of anthracycline-induced 
cardiotoxicity in cancer patients by approximately 75% 
compared to no treatment.12 Dosing of dexrazoxane to 
anthracycline is a 10:1 ratio, respectively. Although dex-
razoxane is a common cardioprotective agent, there is 
insufficient evidence to recommend its use for pediatric 
patients.12 
Mitoxantrone
        Mitoxantrone (Novantrone) is an anthracenedione 
derivative, a relative of the anthracyclines. Its mech-
anism of action is similar to anthracyclines in that it 
intercalates into DNA and causes DNA strand break in 
addition to inhibiting DNA topoisomerase II and pre-
vents DNA replication.2 Mitoxantrone is also associated 
with dose-related cardiotoxicity such as tachycardia, 
arrhythmia, and CHF. The risk of cardiotoxicity increases 
with increased cumulative lifetime dose of mitoxan-
trone, prior anthracycline treatments, prior mediastinal 
radiotherapy and pre-existing cardiovascular disease.13 
Therefore, mitoxantrone treatment is not recommended 
in patients with LVEF < 50% or with clinically significant 
reduction in LVEF while on treatment.14 Mitoxantrone is 
indicated for multiple sclerosis and has a maximum life-
time cumulative dose of 140 mg/m2.14 It is administered 
every 3 months as a short IV infusion (5-15 minutes) as 
opposed to subcutaneous, intramuscular, intrathecal, 
and intra-arterial administrations, which are contraindi-
cated.14 Baseline LVEF should be obtained prior to initia-
tion of mitoxantrone therapy and continually monitored 
throughout treatment. Mitoxantrone is metabolized by 
the liver and reduces the amount of leukocytes. There-
fore, it is not recommended in hepatic insufficiency with 
three-fold elevated enzymes or when neutrophil count is 
< 1500 mm3. Consequently, complete blood count and 
liver function tests should be done prior to each admin-
istration. Mitoxantrone’s side effects include blue-green 
urine days after infusion, sterility, and birth defects, 
which warrant for contraception throughout treatment 
and contraceptive test prior to each administration.15 
Similar to anthracycline, dexrazoxane may be utilized 
to reduce free radical damage of mitoxantrone-induced 
cardiotoxicity with a dosing of dexrazoxane to mitoxan-
trone at 50:1 ratio.16  
Human Epidermal Growth Factor Receptor 2 Protein 
(HER-2) receptor antagonist: trastuzumab
        HER-2 receptor antagonists are humanized IgG1 
kappa monoclonal antibodies that target the human 
epidermal growth factor receptor tyrosine kinase HER-2/
ErbB2 for use in chemotherapy. Their effect on the over-
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expression of HER-2 is due to their selective binding to the 
extracellular HER-2. In recent years, these agents have been 
widely used in the treatment of women with HER2-positive 
breast cancer. However, while useful, their implications in 
cardiomyopathy and other cardiotoxic effects have limited 
their use. Trastuzumab is a HER-2 receptor inhibitor that has 
the most implications with cardiotoxicity in patients.18
        Trastuzumab is one of the older HER-2 receptor antag-
onists that have been associated with cardiotoxicity. Using 
the classification system from the New York Heart Associa-
tion (NYHA) to classify heart failure, the American Heart As-
sociation (AHA) found that HER-2 receptor antagonists have 
been associated with cardiotoxicity as its most debilitating 
side effect.18 The use of trastuzumab in HER2-positive breast 
cancer patients revealed cardiac dysfunction to a large 
extent shown in a large phase III trial.18 The incidence of 
cardiac dysfunction ranged between 4% to 7% when trastu-
zumab is used in monotherapy. However, if combined with 
anthracyclines, this number can reach up to 27%.18 Cardiac 
dysfunction in trastuzumab includes decreased LVEF and 
LVD. The rate of heart failure in patients treated with tras-
tuzumab was significantly higher than those with regimens 
which did not include trastuzumab.19 Risks of cardiotoxicity 
of trastuzumab increases when anthracyclines are used in 
conjunction with or prior to the administration of trasuzum-
ab.18 Hence, more careful monitoring for cardiac function is 
required for patients on these combinations.
       While it is clear that the use of trastuzumab is related to 
cardiac failure, the mechanism of cardiotoxicity is unclear. 
Erb2 is associated in a pathway that is essential for cardio-
myocyte growth, repair, and survival. The mechanism of 
trastuzumab is currently thought to be related to its inhibi-
tion of the signaling cascade of the epidermal growth factor 
that includes cardiomyocyte HER-2 signaling and its ligand 
neuregulin-1. Neuregulin-1 and ErbB4 binding increases the 
activity of the tyrosine kinase, leading to hetero-dimeriza-
tion with Erb2. This increases the signaling potency, which 
controls the survival of cardiomyocytes. Interruption of this 
signaling cascade can result in an ineffective mounting of a 
stress response.18
        Unlike anthracyclines, cardiotoxicities of HER-2 receptor 
antagonists has not been linked to cell death. Rather, car-
diotoxic stress from these agents is more closely associated 
with cardiac dysfunction. Moreover, it is important to note 
that the cardiotoxic effects of HER-2 receptor antagonists 
is not cumulative-dose related. Upon observation using 
electron microscopy, typically ultrasound changes were 
not present. This indicates that the cardiotoxic effects are 
reversible upon discontinuation of the agents. However, 
patients do not demonstrate recovery by a full 100%.19
        To ensure patient safety on trastuzumab, baseline cardi-
ac function is performed prior to therapy using chemother-
apeutic medication. Assessment of this is completed using 
MUGA and ECHO. Patients with normal cardiac function will 
be allowed to proceed with therapy with trastuzumab. 
These are patients with normal LVEF (55-70%). Those 
with intermediate risk factors may begin treatment, but 
must be under increased observation of their health-
care provider to determine the risk-benefit relationship. 
Intermediate risk factors are those with borderline LVEF 
(40-50%), advanced age, and increased cardiac risk.19
       During treatment, patients’ LVEF is closely moni-
tored and their treatment is based on the decrease of 
LVEF. In patients exhibiting a normal ejection fraction 
(EF) with an absolute decrease of greater than 16%, it 
is recommended for the treatment to be held for four 
weeks. If EF falls below the normal range, any decrease 
greater than 10% from baseline is indicative that treat-
ment should be held for four weeks. It is noted that 
these decreases are symptomatic decreases of LVEF.19
Promising HER-2 inhibitors: lapatinib (Tykerb), pertu-
zumab (Perjeta), and trastuzumabemtansine (Kadcyla)
       HER-2 positive breast cancers are associated with a 
poorer prognosis. Because of the high cardiotoxicity of 
trastuzumab that limits its use in chemotherapy, there 
are several recent developments in the treatment of 
HER-2 positive breast cancers. Newer agents used after 
failure or discontinuation of trastuzumab include lapa-
tinib (Tykerb), pertuzumab (Perjeta), and trastuzumab 
emtansine (Kadcyla). These agents are accompanied 
with a lower rate of cardiotoxicity.
        Lapatinib is a reversible inhibitor of HER-2 and 
epidermal growth factor receptor (EGFR). Its approved 
indication is in combination with capecitabine (Xeloda) 
following trastuzumab failure.20 Lapatinib therapy is 
associated with a significantly lower rate of heart failure. 
While cardiotoxicity is seen in animal trials, the bright 
outlook of lapatinib in terms of cardiotoxicity remains 
that its mechanism does not affect the ErbB2-ErbB4 
signaling pathway, which is activated by cardiac cells via 
neuregulin-1. Because of this, lapatinib has exhibited a 
low cardiotoxic profile in comparison to trastuzumab, as 
seen in preliminary data from clinical trials.21
       Pertuzumab is a newer agent in the anti-ErbB2 
family of drugs, which is indicated for HER2-positive 
breast cancer in patients who cannot tolerate or have 
failed trastuzumab. Similar to lapatinib, pertuzumab’s 
mechanism does not involve the ErbB2-ErbB4 signaling 
pathway, which plays a role in its lower cardiotoxicity 
when compared to trastuzumab.14 Additionally, the 
mechanism of action of pertuzumab differs from that of 
trastuzumab in that they recognize different epitopes 
distant from one another, which is thought to play a role 
in their difference in cardiotoxic safety profile.21
        Trastuzumab emtansine (T-DM1) is a combination 
drug, which includes trastuzumab and mertansine 
(DM1). Mertansine is a potent cytotoxic derivative of 
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the antimicrotubule agent maytasine.22 The promising car-
diotoxic profile of T-DM1 is linked with the stability of the 
tioether linker (N-maleimidomethyl) cyclohexan-1-carboxyl-
ate (MCC), which covalently binds trastuzumab and DM1.22 
T-DM1’s more favorable safety profile is associated with its 
mechanism of action. The agent is initially internalized into 
its target cell, where it covalently binds to a lysine, creating a 
positively charged Lys-MCC-MD1. Lys-MCC-MD1 is unable to 
diffuse past the membrane into nearby normal cells. Because 
of this, T-DM1 exudes lower cardiotoxicity than trastuzumab.23 
In addition to its free drug counterpart, trastuzumab, T-DM1 
shows a higher cytotoxicity by delivering a higher drug con-
centration into the HER-2 positive tumor. In a phase II clinical 
trial, T-DM1 exhibited low cardiotoxicity, with no dose reduc-
tion due to decreased cardiac function. While it is noted that 
the pre-screened patient study population had low cardio-
toxic potential, they continued receiving the agent for longer 
than one-year span. This is indicative of a tolerable long-term 
administration of T-DM1. In both phase I and phase II studies, 
cardiotoxicity was not reported with T-DM1.23 Because of its 
lower cardiotoxic profile, T-DM1 is a promising new agent in 
HER-2 positive breast cancers in patients who discontinue 
trastuzumab regimens due to its toxic effect on the heart. 
However, T-DM1 show dose-limiting thrombocytopenia, which 
should be monitored in patients with moderate to high risk.23
5-Fluorouracil
        5-fluorouracil (Adrucil) and its pro-drug capecitabine, 
are pyrimidine antagonist antineoplastic agents under the 
anti-metabolite family indicated in cancers of the breast, 
colorectal, gastric, pancreas, anal, bladder, cervix, bladder, 
esophagus, head and neck, and hepatobiliary pathway. While 
used for many indications, 5-fluorouracil (5-FU) has a several 
cardiac complications, including heart failure, arrhythmia, and 
myocardial ischemia.11 The cardiotoxic effects of 5-FU is seen 
more in patients with a history of cardiac event and is revers-
ible upon discontinuation of the agent.24
        Similar to trastuzumab, the mechanism of toxicity of 
5-FU is unknown. It is theorized that 5-FU induces coronary 
spasms and direct vasoconstriction on smooth muscle cells.25 
However, regardless of this theory, calcium channel blockers 
and nitrates were not seen as beneficial preventative agents 
for the cardiotoxic events. Another theory for 5-FU’s cardiac 
adverse effects is that it is catabolized to fluoroacetate, which 
is a known cardiotoxic substance.26
       One important study by Lamberti et al. showed cardiotoxic 
effects not only in cancer patients, but also in their providing 
healthcare workers who were exposed to the chemo-agents. 
The cause of the providers’ decreased cardiac function was 
not studied, but a correlation exists between their level of 
myocardial dysfunction and the drug concentration of their 
working tables, floors, and air-conditioning. This indicates 
safety and prevention should be performed in both patients 
and their health care providers handling the drug.26
        Additionally, the direct cardiotoxic effects of 5-FU 
are administration dose and frequency related. While 
continuous infusion and bolus dosing are both cardio-
toxic, bolus dosing is associated with a lower cardio-
toxic risk when compared to a prolonged continuous 
infusion regimen.25 24-hour 5-FU continuous infu-
sions was associated with increased cardiac-related 
events when administered for 5 days, when compared 
to a shorter 5-FU administration regimen.26
       Regardless of the dosing differences and mech-
anism of cardiotoxicity, all findings in the Lamberti 
study indicates 5-FU increases oxidative stress on 
cardiomyocytes, which can further lead to apoptosis 
of cardiac cells. Thus, the close cardiac monitoring 
must be considered in all patients on a cancer regi-
men utilizing 5-FU.
Proteasome Inhibitors
       Bortezomib (Velcade) is a reversible dipeptide 
boronate-proteasome inhibitor used for hemato-
logical malignancies. Bortezomib has been shown 
to cause cardiotoxicity in patients, and thus studies 
have recently been performed to test for these toxic 
events. While these studies do not show this agent to 
induce cardiac myocyte death, it does show to cause 
impairment in cardiac function. Studies suggest that 
bortezomib impairs the ubiquitin-proteasome func-
tion, which is crucial in the vitality of cardiac myo-
cytes. Thus, the inhibition of this proteasome pathway 
leads to cardiac dysfunction. The mechanism involves 
increased cardiac stress due to the accumulation of 
poly-ubiquinated proteins. Additionally, this agent 
impacts the heart possibly due to its induction of mi-
tochondrial defects, leading to mitochondrial protein 
translocation. Further studies are needed to confirm 
this mechanism of toxicity. In a systematic review and 
meta-analysis by Xiao et al, there was no significant 
all-grade or high-grade cardiotoxicity risk with borte-
zomib.21 Regardless, the cardiotoxicity of bortezomib 
has not been shown to be reversible, therefore mon-
itoring should be performed in these patients with a 
high baseline cardiac toxicity risk.27
Conclusion
       Oncologic drug-induced cardiotoxicity is a culprit 
in the premature halt of oncologic treatment regimen 
and induction or worsening of preventable cardiotox-
icity. It not only hinders the treatment and progress 
of vulnerable oncologic patients, but it can potentially 
cause fatal or irreversible cardiac adverse events. 
Therefore, pharmacists uphold the crucial responsibil-
ity in recognizing high-risk patients, screening patients 
prior to treatment, monitoring ECHO and MUGA, 
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utilizing cardioprotective agents when applicable, in an 
effort to avert drug-induced cardiotoxicity. Oncologic 
patients are already in a highly vulnerable state; there-
fore, hopeful goals of pharmacologic treatment and 
management should be to improve patients’ quality of 
life and/or disease state, and at the very minimum to 
not harm the patients. As drug experts, pharmacists can 
make an impactful difference in preventing drug-induced 
cardiotoxicity in oncologic patients to optimize patients’ 
treatment outcome and quality of life.  
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